Sugi Predict

Sugi Predict / Compounds / SCHEMBL6535678

SCHEMBL6535678

SCHEMBL6535678

CSCC[C@H](N)C(=O)N[C@H]([C]=O)CC(C)C

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSC P53634 3/20 0.43
▸ CTSB P07858 1/20 0.39
▸ FOLH1 Q04609 1/20 0.38
▸ METAP2 P50579 1/20 0.37
▸ METAP1 P53582 1/20 0.37
▸ DPP4 P27487 2/20 0.34
▸ DPP8 Q6V1X1 2/20 0.34
▸ DPP9 Q86TI2 2/20 0.34
▸ CTSK P43235 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SLC7A5 Q01650 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ FNTA P49354 3/20 0.33
▸ FNTB P49356 3/20 0.33
▸ PGGT1B P53609 2/20 0.33
▸ ANPEP P15144 3/20 0.33
▸ RNPEP Q9H4A4 2/20 0.33
▸ DNPEP Q9ULA0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6535676 1.00 CTSC (0.43) CTSCCTSBFOLH1METAP2METAP1
SCHEMBL2183760 0.91 CTSC (0.39) CTSCCTSBFOLH1METAP2METAP1
SCHEMBL9815784 0.84 CTSC (0.44) CTSCCTSBMETAP2METAP1DPP4
SCHEMBL9514734 0.84 CTSC (0.44) CTSCMETAP2METAP1DPP4DPP8
SCHEMBL10349778 0.84 CTSC (0.44) CTSCMETAP2METAP1DPP4DPP8
SCHEMBL10441973 0.84 CTSC (0.44) CTSCMETAP2METAP1DPP4DPP8
SCHEMBL2192420 0.83 FNTA (0.48) CTSCCTSBFNTAFNTBPGGT1B
SCHEMBL29010817 0.82 SLC7A5 (0.45) CTSCSLC7A5ANPEPRNPEPDNPEP
SCHEMBL21625553 0.82 SLC7A5 (0.45) CTSCSLC7A5ANPEPRNPEPDNPEP
SCHEMBL29010766 0.82 SLC7A5 (0.45) CTSCSLC7A5ANPEPRNPEPDNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114853820-B Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2023-12-15 — — CN claimed
CN-114853820-A Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2022-08-05 — — CN claimed
CN-119836290-A Combination therapy for the treatment of cancer using PRMT5 inhibitors and BCL-2 family inhibitors 米拉蒂治疗公司 2025-04-15 — — CN disclosed
CN-117769421-A Combination therapy for treating cancer using PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-03-26 — — CN disclosed
CN-117769420-A Combination therapy for treating cancer using PRMT5 inhibitors 米拉蒂医疗股份有限公司 2024-03-26 — — CN disclosed
CN-114853820-B Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2023-12-15 — — CN disclosed
CN-114853820-B Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2023-12-15 — — CN disclosed
CN-114853820-A Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2022-08-05 — — CN disclosed
CN-114853820-A Ferrocene and camphorsulfonic acid composite derivative, preparation method thereof and application thereof in catalyzing asymmetric P-S reaction 江苏医药职业学院 2022-08-05 — — CN disclosed
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES AG (AT) 2014-11-27 — — US disclosed
EP-2674161-A1 FMO3 inhibitors for treating pain Akron Molecules GmbH (AT) 2013-12-18 — — EP disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 — — US disclosed
EP-1303290-A4 SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IGE HISTATEK LLC (US) 2004-12-08 — — EP disclosed
EP-1303290-A1 SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IGE Histatek, LLC (US) 2003-04-23 — — EP disclosed
EP-1283715-A1 MODULATON OF ALPHA-6 INTEGRIN-MEDIATED RESPONSES Histatek, LLC (US) 2003-02-19 — — EP disclosed
EP-1162990-A4 TREATMENT WITH SMALL PEPTIDES TO EFFECT ANTIFIBROTIC ACTIVITY HISTATEK LLC (US) 2002-02-06 — — EP disclosed
EP-1162990-A1 TREATMENT WITH SMALL PEPTIDES TO EFFECT ANTIFIBROTIC ACTIVITY Histatek, LLC (US) 2001-12-19 — — EP disclosed
WO-2001089552-A1 MODULATON OF ALPHA-6 INTEGRIN-MEDIATED RESPONSES HISTATEK, LLC (US) 2001-11-29 — — WO disclosed
WO-2001005420-A1 SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IGE HISTATEK, LLC (US) 2001-01-25 — — WO disclosed
WO-2000056349-A1 TREATMENT WITH SMALL PEPTIDES TO EFFECT ANTIFIBROTIC ACTIVITY HISTATEK, LLC (US) 2000-09-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN TRPV1, ACHE, OPRL1 CTSC 778/4885CTSB 345/4885FOLH1 933/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 CTSC 778/4885CTSB 345/4885FOLH1 933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.